MEMS  

 
  MEMS  
About MEMS   |   Council   |   Members Centre   |   Membership   |   Contact Us   |   Home
  Member Login     username:     password:           Forgot your password?
  Home » CME » 
Presidentís Message
The Endocrine Directory
Calendar of Events
Announcements & Updates
Breaking News & Reports
CME
Endocrine Modules
Endocrine Update
Combined Clinical Meeting
CPG
In the Press
Disease Areas
Healthy Lifestyle
Publications
Research Programs
Awards
Photo & Video Gallery
Useful Links
Disease Management
Home
 
arrow

21 December 2015

Summary

The SGLT2 inhibitor, empagliflozin, significantly reduced deaths among individuals with type 2 diabetes and established cardiovascular disease (CVD) when compared with placebo in what is being heralded as a landmark trial.

Please click here for the abstract and full article.



  printer Printer-friendly version   printer Send link to a friend




 
 
| | | |
© Copyright Malaysian Endocrine & Metabolic Society (MEMS)   2009 - 2016    All rights reserved.
designed & maintained: mobition